The National Cancer Institute (NCI) Assay Validation of High Quality Markers for Clinical Studies in Cancer UH3 Grant supports the clinical validation of established molecular, cellular, and imaging biomarker assays for use in future cancer clinical studies and trials.
Projects may focus on markers for cancer detection, diagnosis, prognosis, treatment monitoring, prediction of treatment response or resistance, prevention, and cancer control. Awards provide up to $250,000 in direct costs per year for up to three years, with the next application deadline on October 14, 2026. (Grants.gov)
Eligibility Criteria
- Eligible applicants include public and private institutions of higher education.
- Nonprofit organizations, including those with or without 501(c)(3) status, may apply.
- Foreign/non-U.S. organizations are not eligible to apply.
- Foreign components of eligible U.S. organizations are permitted under NIH policy.
- The investigative team should include appropriate expertise in cancer research/oncology, clinical laboratory science, and biostatistics.
- Clinical trials are not allowed under this funding opportunity.
Funding Details
- Maximum direct costs: $250,000 per year.
- Maximum project duration: 3 years.
- Maximum potential direct-cost funding: $750,000 over three years.
Deadline
- Next application deadline: October 14, 2026.
- Applications are due by 5:00 PM local time of the applicant organization.
- Earliest project start: July 2027.
- NOFO expiration: October 15, 2026.
Further Information
- The program is intended to prepare validated assays for eventual integration into future clinical research rather than to fund the clinical trial itself. (Grants.gov)
- Official program page: View the NIH NOFO
- Simpler.Grants.gov: View the grant opportunity
- Grants.gov: View on Grants.gov